Contract and research manufacturer Dishman Pharmaceuticals has got USFDA approval for Active Pharmaceutical Ingredients (API) production at its Naroda facility here.
"The USFDA team has successfully completed the inspection of Dishman's facility situated at Naroda, in Ahmedabad and has approved the facility for API production for the US market," the company said here today.
The Naroda-based facility of Dishman is an Export Oriented Unit (EOU).
Recently, the company had announced to infuse Rs 125 crore by March end this year, and another Rs 125-150 crore next year for opening two new API units, as part of its capex expansion plans.
According to company officials, the group's topline business has been under pressure in the third quarter and the year has been flat so far.
The business coming from our Swiss arm Carbogen Amics went down nearly by 40 per cent, but company order book is robust and outlook for the next fiscal is bright, it added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app